Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...
A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...
The "Nebulizer Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Global Nebulizer Market is expected to reach US$ 2 ...
BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA ...
Q3 2025 Management View Jonathan Solomon, CEO, stated that the third quarter of 2025 was an important period for BiomX, ...
After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer therapy ...
People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...
A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light on the prevalence and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback